Essential roles of PI-3K/Akt/IKKβ/NFκB pathway in cyclin D1 induction by arsenite in JB6 Cl41 cells

Carcinogenesis

Volumn 27, Issue 4, 2006, Pages 864-873

  Ouyang, Weiming ^a   Li, Jingxia ^a   Ma, Qian ^a   Huang, Chuanshu ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CYCLIN D1; I KAPPA B; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P85; S6 KINASE; WORTMANNIN;

ANIMAL CELL; ARTICLE; CARCINOGENIC ACTIVITY; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME DEGRADATION; EPIDERMIS CELL; EXPOSURE; GENE EXPRESSION; GENE OVEREXPRESSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKIN;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ARSENITES; CELL CULTURE TECHNIQUES; CELL CYCLE; CELL PROLIFERATION; CYCLIN D1; EPIDERMIS; I-KAPPA B KINASE; MICE; NF-KAPPA B; ONCOGENE PROTEIN V-AKT; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; SKIN PHYSIOLOGY; TERATOGENS;

EID: 33645304305     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgi321     Document Type: Article

References (79)

1. Nriagu,J.O. (2002) Environmental Chemistry of Arsenic. Dekker, New York.
2. Bettley,F.R. and O'Shea,J.A. (1975) The absorption of arsenic and its relation to carcinoma. Br. J. Dermatol., 92, 563-568.
3. Landolph,J.R. (1994) Molecular mechanisms of transformation of C3H/10T1/ 2 C1 8 mouse embryo cells and diploid human fibroblasts by carcinogenic metal compounds. Environ. Health Perspect., 102 Suppl. 3, 119-125.
4. Cancer,I.A.f.R.o. (1980) IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man, Some Metals and Metallic Compounds, Lyon, France.
5. Council,N.R. (2000) Arsenic in Drinking Water. National Academy Press, Washington, DC.
6. Germolec,D.R., Yoshida,T., Gaido,K., Wilmer,J.L., Simeonova,P.P., Kayama,F., Burleson,F., Dong,W., Lange,R.W. and Luster,M.I. (1996) Arsenic induces overexpression of growth factors in human keratinocytes. Toxicol. Appl. Pharmacol., 141, 308-318.
7. Hamadeh,H.K., Trouba,K.J., Amin,R.P., Afshari,C.A. and Germolec,D. (2002) Coordination of altered DNA repair and damage pathways in arsenite-exposed keratinocytes. Toxicol. Sci., 69, 306-316.
8. Simeonova,P.P., Wang,S., Toriuma,W. et al. (2000) Arsenic mediates cell proliferation and gene expression in the bladder epithelium: Association with activating protein-1 transactivation. Cancer Res., 60, 3445-3453.
9. Van Wijk,R., Welters,M., Souren,J.E., Ovelgonne,H. and Wiegant,F.A. (1993) Serum-stimulated cell cycle progression and stress protein synthesis in C3H10T1/2 fibroblasts treated with sodium arsenite. J. Cell Physiol., 155, 265-272.
10. Burns,F.J., Uddin,A.N., Wu,F., Nadas,A. and Rossman,T.G. (2004) Arsenic-induced enhancement of ultraviolet radiation carcinogenesis in mouse skin: A dose-response study. Environ. Health Perspect., 112, 599-603.
11. Germolec,D.R., Spalding,J., Boorman,G.A. et al. (1997) Arsenic can mediate skin neoplasia by chronic stimulation of keratinocyte-derived growth factors. Mutat. Res., 386, 209-218.
12. Germolec,D.R., Spalding,J., Yu,H.S. et al. (1998) Arsenic enhancement of skin neoplasia by chronic stimulation of growth factors. Am. J. Pathol., 153, 1775-1785.
13. Rossman,T.G., Uddin,A.N. and Burns,F.J. (2004) Evidence that arsenite acts as a cocarcinogen in skin cancer. Toxicol. Appl. Pharmacol., 198, 394-404.
14. 1 cell-cycle control and cancer. Nature, 432, 298-306.
15. Kastan,M.B. and Bartek,J. (2004) Cell-cycle checkpoints and cancer. Nature, 432, 316-323.
16. Johnson,D.G. and Walker,C.L. (1999) Cyclins and cell cycle checkpoints. Annu. Rev. Pharmacol. Toxicol., 39, 295-312.
17. Arber,N., Doki,Y., Han,E.K., Sgambato,A., Zhou,P., Kim,N.H., Delohery,T., Klein,M.G., Holt,P.R. and Weinstein,I.B. (1997) Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res., 57, 1569-1574.
18. Sauter,E.R., Nesbit,M., Litwin,S., Klein-Szanto,A.J., Cheffetz,S. and Herlyn,M. (1999) Antisense cyclin D1 induces apoptosis and tumor shrinkage in human squamous carcinomas. Cancer Res., 59, 4876-4881.
19. Tchounwou,P.B., Yedjou,C.G. and Dorsey,W.C. (2003) Arsenic trioxide-induced transcriptional activation of stress genes and expression of related proteins in human liver carcinoma cells (HepG2). Cell Mol. Biol. (Noisyle-grand), 49, 1071-1079.
20. Huang,C., Ke,Q., Costa,M. and Shi,X. (2004) Molecular mechanisms of arsenic carcinogenesis. Mol. Cell Biochem., 255, 57-66.
21. Vogt,B.L. and Rossman,T.G. (2001) Effects of arsenite on p53, p21 and cyclin D expression in normal human fibroblasts - a possible mechanism for arsenite's comutagenicity. Mutat. Res., 478, 159-168.
22. Li,J., Davidson,G., Huang,Y., Jiang,B.H., Shi,X, Costa,M. and Huang,C. (2004) Nickel compounds act through phosphatidylinositol-3-kinase/ Akt-dependent, p70(S6k)-independent pathway to induce hypoxia inducible factor transactivation and Cap43 expression in mouse epidermal Cl41 cells. Cancer Res., 64, 94-101.
23. Huang,C., Ma,W.Y. and Dong,Z. (1996) Requirement for phosphatidylinositol 3-kinase in epidermal growth factor-induced AP-1 transactivation and transformation in JB6 P+ cells. Mol. Cell. Biol., 16, 6427-6435.
24. Huang,C., Schmid,P.C., Ma,W.Y., Schmid,H.H. and Dong,Z. (1997) Phosphatidylinositol-3 kinase is necessary for 12-O-tetradecanoylphorbol-13-acetate-induced cell transformation and activated protein 1 activation. J. Biol. Chem., 272, 4187-4194.
25. Huang,C., Li,J., Ding,M., Leonard,S.S., Wang,L., Castranova,V., Vallyathan,V. and Shi,X. (2001) UV Induces phosphorylation of protein kinase B (Akt) at Ser-473 and Thr-308 in mouse epidermal Cl 41 cells through hydrogen peroxide. J. Biol. Chem., 276, 40234-40240.
26. Yan,Y.X., Nakagawa,H., Lee,M.H. and Rustgi,A.K. (1997) Transforming growth factor-alpha enhances cyclin D1 transcription through the binding of early growth response protein to a cis-regulatory element in the cyclin D1 promoter. J. Biol. Chem., 272, 33181-33190.
27. 1-S phase transition in human keratinocytes. Cancer Res., 65, 9287-9293.
28. Huang,C., Ma,W., Ding,M., Bowden,G.T. and Dong,Z. (1997) Direct evidence for an important role of sphingomyelinase in ultraviolet-induced activation of c-Jun N-terminal kinase. J. Biol. Chem, 272, 27753-27757.
29. Sherr,C.J. (1996) Cancer cell cycles. Science, 274, 1672-1677.
30. Peters,G. (1994) The D-type cyclins and their role in tumorigenesis. J. Cell Sci., 18 (Suppl), 89-96.
31. Brunet,A., Datta,S.R. and Greenberg,M.E. (2001) Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr. Opin. Neurobiol., 11, 297-305.
32. Krasilnikov,M.A. (2000) Phosphatidylinositol-3 kinase dependent pathways: The role in control of cell growth, survival, and malignant transformation. Biochemistry (Mosc.), 65, 59-67.
33. Franke,T.F., Kaplan,D.R., Cantley,L.C. and Toker,A. (1997) Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3, 4-bisphosphate. Science, 275, 665-668.
34. Franke,T.F., Kaplan,D.R. and Cantley,L.C. (1997) PI3K: Downstream AKTion blocks apoptosis. Cell, 88, 435-437.
35. Manning,B.D. and Cantley,L.C. (2003) United at last: The tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/ Akt pathway to mammalian target of rapamycin (mTOR) signalling. Biochem. Soc. Trans., 31, 573-578.
36. Ozes,O.N., Mayo,L.D., Gustin,J.A., Pfeffer,S.R., Pfeffer,L.M. and Donner,D.B. (1999) NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature, 401, 82-85.
37. Eder,A.M., Dominguez,L., Franke,T.F. and Ashwell,J.D. (1998) Phosphoinositide 3-kinase regulation of T cell receptor-mediated interleukin-2 gene expression in normal T cells. J. Biol. Chem., 273, 28025-28031.
38. Ryves,W.J. and Harwood,A.J. (2003) The interaction of glycogen synthase kinase-3 (GSK-3) with the cell cycle. Prog. Cell Cycle Res., 5, 489-495.
39. Huang,C., Li,J., Ding,M., Wang,L., Shi,X., Castranova,V., Vallyathan,V., Ju,G. and Costa,M. (2001) Arsenic-induced NFkappaB transactivation through Erks- and JNKs-dependent pathways in mouse epidermal JB6 cells. Mol. Cell Biochem., 222, 29-34.
40. Karin,M. and Delhase,M. (2000) The I kappa B kinase (IKK) and NF-kappa B: Key elements of proinflammatory signalling. Semin. Immunol., 12, 85-98.
41. See,V., Rajala,N.K., Spiller,D.G. and White,M.R. (2004) Calcium-dependent regulation of the cell cycle via a novel MAPK-NF-kappaB pathway in Swiss 3T3 cells. J. Cell Biol., 166, 661-672.
42. 1. Genes Dev., 7, 812-821.
43. Guttridge,D.C., Albanese,C., Reuther,J.Y., Pestell,R.G. and Baldwin,A.S.,Jr (1999) NF-kappaB controls cell growth and differentiation through transcriptional regulation of cychn D1. Mol. Cell. Biol., 19, 5785-5799.
44. 1-to-S-phase transition. Mol. Cell. Biol., 19, 2690-2698.
45. Joyce,D., Bouzahzah,B., Fu,M. et al. (1999) Integration of Rac-dependent regulation of cyclin D1 transcription through a nuclear factor-kappaB-dependent pathway. J. Biol. Chem., 274, 25245-25249.
46. Watanabe,G., Lee,R.J., Albanese,C., Rainey,W.E., Batlle,D. and Pestell,R.G. (1996) Angiotensin II activation of cyclin D1-dependent kinase activity. J. Biol. Chem., 271, 22570-22577.
47. Lee,R.J., Albanese,C., Stenger,R.J. et al. (1999) pp60(v-src) induction of cyclin D1 requires collaborative interactions between the extracellular signal-regulated kinase, p38, and Jun kinase pathways. A role for cAMP response element-binding protein and activating transcription factor-2 in pp60(v-src) signaling in breast cancer cells. J. Biol. Chem., 274, 7341-7350.
48. Matsumura,I., Kitamura,T., Wakao,H., Tanaka,H., Hashimoto,K., Albanese,C., Downward,J., Pestell,R.G. and Kanakura,Y. (1999) Transcriptional regulation of the cyclin D1 promoter by STAT5: Its involvement in cytokine-dependent growth of hematopoietic cells. EMBO J., 18, 1367-1377.
49. Lee,R.J., Albanese,C., Fu,M. et al. (2000) Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol. Cell. Biol., 20, 672-683.
50. Pradeep,A., Sharma,C., Sathyanarayana,P., Albanese,C., Fleming,J.V., Wang,T.C., Wolfe,M.M., Baker,K.M., Pestell,R.G. and Rana,B. (2004) Gastrin-mediated activation of cyclin D1 transcription involves beta-catenin and CREB pathways in gastric cancer cells. Oncogene, 23, 3689-3699.
51. Sabbah,M., Courilleau,D., Mester,J. and Redeuilh,G. (1999) Estrogen induction of the cyclin D1 promoter: Involvement of a cAMP response-like element. Proc. Natl Acad Sci. USA, 96, 11217-11222.
52. Nagata,D., Suzuki,E., Nishimatsu,H., Satonaka,H., Goto,A., Omata,M. and Hirata,Y. (2001) Transcriptional activation of the cyclin D1 gene is mediated by multiple cis-elements, including SP1 sites and a cAMP-responsive element in vascular endothelial cells. J. Biol. Chem., 276, 662-669.
53. Watanabe,G., Albanese,C., Lee,R.J., Reutens,A., Vairo,G., Henglein,B. and Pestell,R.G. (1998) Inhibition of cyclin D1 kinase activity is associated with E2F-mediated inhibition of cyclin D1 promoter activity through E2F and Sp1. Mol. Cell. Biol., 18, 3212-3222.
54. Jeong,S.J., Pise-Masison,C.A., Radonovich,M.F., Park,H.U. and Brady,J.N. (2005) Activated AKT regulates NF-kappaB activation, p53 inhibition and cell survival in HTLV-1-transformed cells. Oncogene, 24, 6719-6728.
55. Vandermoere,F., El Yazidi-Belkoura,I., Adriaenssens,E., Lemoine,J. and Hondermarck,H. (2005) The antiapoptotic effect of fibroblast growth factor-2 is mediated through nuclear factor-kappaB activation induced via interaction between Akt and IkappaB kinase-beta in breast cancer cells. Oncogene, 24, 5482-5491.
56. Kapahi,P., Takahashi,T., Natoli,G., Adams,S.R., Chen,Y., Tsien,R.Y. and Karin,M. (2000) Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. J. Biol. Chem., 275, 36062-36066.
57. Hu,Y., Baud,V., Delhase,M., Zhang,P., Deerinck,T., Ellisman,M., Johnson,R. and Karin,M. (1999) Abnormal morphogenesis but intact IKK activation in mice lacking the IKKalpha subunit of IkappaB kinase. Science, 284, 316-320.
58. Li,Q., Lu,Q., Hwang,J.Y., Buscher,D., Lee,K.F., Izpisua-Belmonte,J.C. and Verma,I.M. (1999) IKK1-deficient mice exhibit abnormal development of skin and skeleton. Genes Dev., 13, 1322-1328.
59. Hu,Y., Baud,V., Oga,T., Kim,K.I., Yoshida,K. and Karin,M. (2001) IKKalpha controls formation of the epidermis independently of NF-kappaB. Nature, 410, 710-714.
60. Seitz,C.S., Lin,Q., Deng,H. and Khavari,P.A. (1998) Alterations in NF-kappaB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-kappaB. Proc. Natl Acad. Sci. USA, 95, 2307-2312.
61. Pasparakis,M., Courtois,G., Hafner,M. et al. (2002) TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. Nature, 417, 861-866.
62. Klement,J.F., Rice,N.R., Car,B.D., Abbondanzo,S.J., Powers,G.D., Bhatt,P.H., Chen,C.H., Rosen,C.A. and Stewart,C.L. (1996) IkappaBalpha deficiency results in a sustained NF-kappaB response and severe wide-spread dermatitis in mice. Mol. Cell. Biol., 16, 2341-2349.
63. Nikolopoulos,S.N., Blaikie,P., Yoshioka,T., Guo,W., Puri,C., Tacchetti,C. and Giancotti,F.G. (2005) Targeted deletion of the integrin beta4 signaling domain suppresses laminin-5-dependent nuclear entry of mitogen-activated protein kinases and NF-kappaB, causing defects in epidermal growth and migration. Mol. Cell. Biol., 25, 6090-6102.
64. Budunova,I.V., Perez,P., Vaden,V.R., Spiegelman,V.S., Slaga,T.J. and Jorcano,J.L. (1999) Increased expression of p50-NF-kappaB and constitutive activation of NF-kappaB transcription factors during mouse skin carcinogenesis. Oncogene, 18, 7423-7431.
65. Pandolfi,F., Trentin,L., Boyle,L.A., Stamenkovic,I., Byers,H.R., Colvin,R.B. and Kumick,J.T. (1992) Expression of cell adhesion molecules in human melanoma cell lines and their role in cytotoxicity mediated by tumor-infiltrating lymphocytes. Cancer, 69, 1165-1173.
66. Diehl,J.A., Cheng,M., Roussel,M.F. and Sherr,C.J. (1998) Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev., 12, 3499-3511.
67. Rimerman,R.A., Gellert-Randleman,A. and Diehl,J.A. (2000) Wnt1 and MEK1 cooperate to promote cyclin D1 accumulation and cellular transformation. J. Biol. Chem., 275, 14736-14742.
68. Huang,C., Bode,A.M., Chen,N.Y., Ma,W.Y., Li,J., Nomura,M. and Dong,Z. (2001) Transactivation of AP-1 in AP-1-luciferase reporter transgenic mice by arsenite and arsenate. Anticancer Res., 21, 261-267.
69. Sherr,C.J. (2000) The Pezcoller lecture: Cancer cell cycles revisited. Cancer Res., 60, 3689-3695.
70. Stacey,D.W. (2003) Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Curr. Opin. Cell Biol., 15, 158-163.
71. 0-arrestable cancer cell line. Exp. Cell Res., 225, 85-92.
72. Barnes,D.M. and Gillett,C.E. (1998) Cyclin D1 in breast cancer. Breast Cancer Res. Treat., 52, 1-15.
73. Weinstein,I.B. (2000) Disorders in cell circuitry during multistage carcinogenesis: The role of homeostasis. Carcinogenesis, 21, 857-864.
74. Fusenig,N.E. and Boukamp,P. (1998) Multiple stages and genetic alterations in immortalization, malignant transformation, and tumor progression of human skin keratinocytes. Mol. Carcinog., 23, 144-158.
75. Nichols,G.E., Williams,M.E., Gaffey,M.J. and Stoler,M.H. (1996) Cyclin D1 gene expression in human cervical neoplasia. Mod. Pathol., 9, 418-425.
76. Worsley,S.D., Ponder,B.A. and Davies,B.R. (1997) Overexpression of cyclin D1 in epithelial ovarian cancers. Gynecol. Oncol., 64, 189-195.
77. Michalides,R., Hageman,P., van Tinteren,H., Houben,L., Wientjens,E., Klompmaker,R. and Peterse,J. (1996) A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br. J. Cancer, 73, 728-734.
78. Proctor,A.J., Coombs,L.M., Cairns,J.P. and Knowles,M.A. (1991) Amplification at chromosome 11q13 in transitional cell tumours of the bladder. Oncogene, 6, 789-795.
79. Semczuk,A. and Jakowicki,J.A. (2004) Alterations of pRb1-cyclin D1-cdk4/ 6-p16(INK4A) pathway in endometrial carcinogenesis. Cancer Lett., 203, 1-12.